Bottom line
FTXH vs PRHSX: the short answer
FTXH (First Trust Nasdaq Pharmaceuticals ETF) and PRHSX (T. Rowe Price Health Sciences Fund, Inc.) are both etfs.
But PRHSX is far broader, holding 279 positions to 51 for FTXH, so beyond the top names it adds exposure FTXH doesn't have.
FTXH is cheaper at 0.6% vs 0.83% — a difference of $23 a year per $10,000 invested.
Over five years, FTXH returned +6.5% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
FTXH vs PRHSX side by side
| FTXH | PRHSX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | First Trust | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.6% | 0.83% |
| Annual cost per $10k | $60 | $83 |
| 10-yr cost on $10k (prospectus) | — | $1,025 |
| Max front load | None | — |
| 12b-1 fee | 0% | — |
| 1-yr return | +24.0% | +17.7% |
| 5-yr return (annualized) | +6.5% | +4.2% |
| 10-yr return (annualized) | — | +9.1% |
| Best quarter | +18.3% | +23.5% |
| Worst quarter | −17.4% | −15.8% |
| Net assets (fund) | $36.2M | $11.9B |
| Number of holdings | 51 | 279 |
| Portfolio turnover | 35% | 62% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FTXH | PRHSX | Difference |
|---|---|---|---|
| 2025 | +24.0% | +17.7% | +6.3% |
| 2024 | +3.0% | +1.8% | +1.1% |
| 2023 | −1.4% | +3.1% | −4.5% |
| 2022 | +2.5% | −12.2% | +14.7% |
| 2021 | +6.1% | +13.3% | −7.2% |
| 2020 | +10.9% | +30.1% | −19.3% |
| 2019 | +22.4% | +29.1% | −6.8% |
| 2018 | −8.4% | +1.2% | −9.6% |
| 2017 | +18.8% | +28.0% | −9.2% |
Source: Fund prospectus bar charts
Holdings overlap
9 of FTXH's top 25 holdings also appear in PRHSX's top 25.
| Holding | FTXH | PRHSX |
|---|---|---|
| Eli Lilly & Company | 7.77% | 14.28% |
| Abbvie Inc | 7.39% | 5.10% |
| Merck & Company Inc | 7.07% | 4.01% |
| Johnson & Johnson | 6.96% | 6.63% |
| Bristol-myers Squibb Company | 6.29% | 2.11% |
| Cardinal Health Inc | 3.53% | 1.03% |
| Vertex Pharmaceuticals Inc | 3.41% | 2.28% |
| Amgen Inc | 3.18% | 1.82% |
| Gilead Sciences Inc | 2.89% | 2.82% |
Source: SEC Form N-PORT
FTXH top 10
- Eli Lilly & Company — 7.77%
- Abbvie Inc — 7.39%
- Merck & Company Inc — 7.07%
- Johnson & Johnson — 6.96%
- Bristol-myers Squibb Company — 6.29%
- Biogen Inc — 3.84%
- Viatris Inc — 3.62%
- Cardinal Health Inc — 3.53%
- Vertex Pharmaceuticals Inc — 3.41%
- Amgen Inc — 3.18%
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
FAQ
What is the difference between FTXH and PRHSX?
Which is cheaper, FTXH or PRHSX?
Should I own both FTXH and PRHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.